The BC subtype proportions in this cohort were as follows: 48% HR( +)/HER2( − ), 22.6% HR( − )/HER2( − ), 16.8% HR( +)/HER2( +), and 12.6% HR(−)/HER2( +). Here, ERBB2 is linked to breast cancer.